Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model
Authors:
- Nele GoeyvaertsNGNele Goeyvaerts
- Xavier Woot de TrixheXTXavier Woot de Trixhe
- Martine NeyensMNMartine Neyens
- Thomas N. KakudaTKThomas N. Kakuda
- Liesbeth Van WesenbeeckLWLiesbeth Van Wesenbeeck
- Annemie BuelensABAnnemie Buelens
- Freya RasschaertFRFreya Rasschaert
- Anna DurbinADAnna Durbin
- Oliver AckaertOAOliver Ackaert
Open Access
- 9 August 2026
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1379-1388
Abstract
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.Keywords
This publication has 32 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult ParticipantsClinical Pharmacology in Drug Development, 2025
- Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in NicaraguaThe Lancet Infectious Diseases, 2024
- Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formationNature Communications, 2024
- A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interactionNature, 2021
- Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of TherapeuticsClinical Pharmacology & Therapeutics, 2021
- Prevalence of dengue antibodies in healthy children and adults in different Colombian endemic areasInternational Journal of Infectious Diseases, 2020
- Viral kinetic modeling: state of the artJournal of Pharmacokinetics and Pharmacodynamics, 2014
- A Comprehensive Hepatitis C Viral Kinetic Model Explaining CureClinical Pharmacology & Therapeutics, 2010
- Basic PK/PD principles of drug effects in circular/proliferative systems for disease modellingJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Likelihood based approaches to handling data below the quantification limit using NONMEM VIJournal of Pharmacokinetics and Pharmacodynamics, 2008